Matthew O'Brien

“On renal denervation, I just want to be sure I'm clear on the message here because obviously Cass is doing really well. So how are you thinking about the trajectory of that business now, the market opportunity, any updates on what you're thinking in terms of the market?”

“Maybe, for starters, on the guidance side of things, if you look at the – it's good to see a bump up in the back half of the year, and I understand seasonality and mixed changes, but this time last year you saw a pretty meaningful bump up second half of the year versus the first half, this year it's essentially flat…”

“Maybe Leo was just talking about the guide in the back half. It's good to see you bumping it up by more than a beat here in Q2, but it does still imply a little bit of a D-cell second half versus first half.”

“For starters, maybe Anshul, just on the guide for the year, you know, good to see Q2 come in a little bit above expectations. But if you do the math on the back half, it's about a $500,000 increase to the midpoint, you know, versus a million that you just put up.”

“Kevin or Preston, I hate to keep harping on this, this back half, because I think everybody's really nervous now about your ability to hit the back half numbers, but you keep talking about this production ramp, your facilities being able to meet this sizable ramp in the back half.”